{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:08:37Z","timestamp":1791616117589,"version":"4.3.4"},"reference-count":32,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T00:00:00Z","timestamp":1670716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"United States Department of Veterans Affairs Merit","award":["VA-ORD I01 BX004974"],"award-info":[{"award-number":["VA-ORD I01 BX004974"]}]},{"name":"United States Department of Veterans Affairs Merit","award":["W81XWH2210631"],"award-info":[{"award-number":["W81XWH2210631"]}]},{"name":"United States Department of Veterans Affairs Merit","award":["UL1TR00188"],"award-info":[{"award-number":["UL1TR00188"]}]},{"DOI":"10.13039\/100000005","name":"Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program","doi-asserted-by":"publisher","award":["VA-ORD I01 BX004974"],"award-info":[{"award-number":["VA-ORD I01 BX004974"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH2210631"],"award-info":[{"award-number":["W81XWH2210631"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program","doi-asserted-by":"publisher","award":["UL1TR00188"],"award-info":[{"award-number":["UL1TR00188"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"Iris Cantor-UCLA Women\u2019s Health Center\/UCLA National Center of Excellence","doi-asserted-by":"publisher","award":["VA-ORD I01 BX004974"],"award-info":[{"award-number":["VA-ORD I01 BX004974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"Iris Cantor-UCLA Women\u2019s Health Center\/UCLA National Center of Excellence","doi-asserted-by":"publisher","award":["W81XWH2210631"],"award-info":[{"award-number":["W81XWH2210631"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"Iris Cantor-UCLA Women\u2019s Health Center\/UCLA National Center of Excellence","doi-asserted-by":"publisher","award":["UL1TR00188"],"award-info":[{"award-number":["UL1TR00188"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sandy Rollman Ovarian Cancer Foundation","award":["VA-ORD I01 BX004974"],"award-info":[{"award-number":["VA-ORD I01 BX004974"]}]},{"name":"Sandy Rollman Ovarian Cancer Foundation","award":["W81XWH2210631"],"award-info":[{"award-number":["W81XWH2210631"]}]},{"name":"Sandy Rollman Ovarian Cancer Foundation","award":["UL1TR00188"],"award-info":[{"award-number":["UL1TR00188"]}]},{"name":"Annenberg Foundation","award":["VA-ORD I01 BX004974"],"award-info":[{"award-number":["VA-ORD I01 BX004974"]}]},{"name":"Annenberg Foundation","award":["W81XWH2210631"],"award-info":[{"award-number":["W81XWH2210631"]}]},{"name":"Annenberg Foundation","award":["UL1TR00188"],"award-info":[{"award-number":["UL1TR00188"]}]},{"name":"Tina\u2019s Wish Foundation","award":["VA-ORD I01 BX004974"],"award-info":[{"award-number":["VA-ORD I01 BX004974"]}]},{"name":"Tina\u2019s Wish Foundation","award":["W81XWH2210631"],"award-info":[{"award-number":["W81XWH2210631"]}]},{"name":"Tina\u2019s Wish Foundation","award":["UL1TR00188"],"award-info":[{"award-number":["UL1TR00188"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Ciliated cell markers expressed in epithelial ovarian cancers (EOC) are associated with improved survival. We examined the distribution of cells expressing ciliated cell markers in various EOC histologies and stages. Immunohistochemistry and\/or multiplex immunofluorescence were used to determine the expression of FOXJ1 and\/or CAPS (ciliated cell markers) in tissue microarrays including 4 normal fallopian tubes, 6 normal endometria, 16 cystadenomas, 25 borderline tumors, 21 low-grade carcinomas, and 118 high-grade carcinomas (HGSOC) (46 serous, 29 endometrioid, 30 clear cell, 13 mucinous). CAPS+ cells were observed in normal fallopian tubes and endometria and in ~85% of serous benign and borderline tumors and low-grade carcinomas but only in &lt;40% of HGSOC. mRNA data from an independent cohort showed higher FOXJ1 and CAPS expression in serous borderline tumors and low-grade carcinomas compared to HGSOC. In HGSOC, ciliated cell-positive markers were observed in 52% primary tumors compared to 26% of patient-matched synchronous metastases, and 24% metachronous metastases (p = 0.009). mRNA data from an independent HGSOC cohort showed lower levels of CAPS in metastases than in primary tumors (p = 0.03). Overall, the study revealed that ciliated cells were less common in mucinous EOC, the percentage of ciliated cell marker-positive cases decreased with increasing grade, and the percentage of ciliated cells decreased in HGSOC metastases compared to patient-matched primary tumors.<\/jats:p>","DOI":"10.3390\/cells11244009","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T03:36:09Z","timestamp":1670816169000},"page":"4009","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3011-1591","authenticated-orcid":false,"given":"Michael T.","family":"Richardson","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-9381","authenticated-orcid":false,"given":"Maria Sol","family":"Recouvreux","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-2933","authenticated-orcid":false,"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Walts","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-8721","authenticated-orcid":false,"given":"Sandra","family":"Orsulic","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA"},{"name":"VA Greater Los Angeles Healthcare System, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/IGC.0000000000000282","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)","volume":"24","author":"Harter","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Coan, M., Rampioni Vinciguerra, G.L., Cesaratto, L., Gardenal, E., Bianchet, R., Dassi, E., Vecchione, A., Baldassarre, G., Spizzo, R., and Nicoloso, M.S. (2018). Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092512"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5","article-title":"Extraovarian peritoneal serous papillary carcinoma. A Clin. icopathologic study of 31 cases","volume":"64","author":"Dalrymple","year":"1989","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1530\/ERC-11-0107","article-title":"The impact of ovulation on fallopian tube epithelial cells: Evaluating three hypotheses connecting ovulation and serous ovarian cancer","volume":"18","author":"King","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1535370213508216","article-title":"Altered expression of inflammation-associated genes in oviductal cells following follicular fluid exposure: Implications for ovarian carcinogenesis","volume":"239","author":"Lau","year":"2014","journal-title":"Exp. Biol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ygyno.2017.02.033","article-title":"Updates of the role of oxidative stress in the pathogenesis of ovarian cancer","volume":"145","author":"Saed","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/humupd\/dml012","article-title":"The reproductive significance of human Fallopian tube cilia","volume":"12","author":"Lyons","year":"2006","journal-title":"Hum Reprod Update"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.4934","article-title":"Clear cell and endometrioid carcinomas: Are their differences attributable to distinct cells of origin?","volume":"243","author":"Cochrane","year":"2017","journal-title":"J. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PGP.0000000000000120","article-title":"Two types of ovarian cortical inclusion cysts: Proposed origin and possible role in ovarian serous carcinogenesis","volume":"34","author":"Banet","year":"2015","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jcp.52.5.355","article-title":"Application of a marker of ciliated epithelial cells to gynaecological pathology","volume":"52","author":"Comer","year":"1999","journal-title":"J. Clin. Ical Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/his.13444","article-title":"Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy","volume":"72","author":"Park","year":"2018","journal-title":"Histopathology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/onc.2015.62","article-title":"Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis","volume":"35","author":"George","year":"2016","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/onc.2009.402","article-title":"Primary ex vivo cultuRes. of human fallopian tube epithelium as a model for serous ovarian carcinogenesis","volume":"29","author":"Levanon","year":"2010","journal-title":"Oncogene"},{"key":"ref_18","unstructured":"Weir, A., Kang, E.Y., Meagher, N.S., Nelson, G.S., Ghatage, P., Lee, C.H., Riggan, M.J., Gentry-Maharaj, A., Ryan, A., and Singh, N. (2022). Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: An Ovarian Tumor Tissue Analysis Consortium Study. Br. J. Cancer, 1\u201311."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"43843","DOI":"10.18632\/oncotarget.5983","article-title":"CSIOVDB: A microarray gene expression database of epithelial ovarian cancer subtype","volume":"6","author":"Tan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_20","first-page":"3815","article-title":"Loss of tubal ciliated cells as a risk for \"ovarian\" or pelvic serous carcinoma","volume":"10","author":"Tao","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"853755","DOI":"10.3389\/fonc.2022.853755","article-title":"Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma","volume":"12","author":"Wu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3121\/cmr.2007.702","article-title":"Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer","volume":"5","author":"Crum","year":"2007","journal-title":"Clin. Med. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am. J. Surg Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/PAS.0b013e318233b0f7","article-title":"Fallopian tube correlates of ovarian serous borderline tumors","volume":"35","author":"Laury","year":"2011","journal-title":"Am. J. Surg Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.prp.2017.02.001","article-title":"Frequency of papillary tubal hyperplasia (PTH), salpingoliths and transition from adenoma to borderline ovarian tumors (BOT): A systematic analysis of 74 BOT with different histologic types","volume":"213","author":"Horn","year":"2017","journal-title":"Pathol. Res. Pract"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/s41467-019-11862-x","article-title":"The molecular origin and taxonomy of mucinous ovarian carcinoma","volume":"10","author":"Cheasley","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/IGC.0000000000000296","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma","volume":"24","author":"Ledermann","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra1813254","article-title":"Mucinous Ovarian Carcinoma","volume":"380","author":"Morice","year":"2019","journal-title":"N Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Babaier, A., and Ghatage, P. (2020). Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics, 10.","DOI":"10.3390\/diagnostics10010052"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/PAI.0b013e3181672574","article-title":"Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities","volume":"16","author":"Lin","year":"2008","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Meagher, N.S., Gorringe, K.L., Wakefield, M.J., Bolithon, A., Pang, C.N.I., Chiu, D.S., Anglesio, M.S., Mallitt, K.A., Doherty, J.A., and Harris, H.R. (2022). Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes. Clin. Cancer Res., 1206.","DOI":"10.1158\/1078-0432.CCR-22-1206"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/1078-0432.CCR-20-2782","article-title":"The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/24\/4009\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:39:23Z","timestamp":1760146763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/24\/4009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,11]]},"references-count":32,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cells11244009"],"URL":"https:\/\/doi.org\/10.3390\/cells11244009","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,11]]}}}